Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Breast 1

Conditions

Prostatic Neoplasms 3Leukemia 2Waldenstrom Macroglobulinemia 1Uveal Melanoma 1Triple Negative Breast Neoplasms 1Stomatitis 1Neoplasms 1Neoplasm Metastasis 1Melanoma 1Lung Neoplasms 1Leukemia, Lymphocytic, Chronic, B-Cell 1Head and Neck Neoplasms 1Glioma 1Glioblastoma 1Epstein-Barr Virus Infections 1Cytomegalovirus Infections 1Carcinoma, Non-Small-Cell Lung 1Astrocytoma 1Adenocarcinoma 1

Interventions

Carboplatin 358Pemetrexed 275Cisplatin 229Paclitaxel 212Docetaxel 205Gemcitabine 160Erlotinib Hydrochloride 150Bevacizumab 132pembrolizumab 128Radiotherapy 112Nivolumab 88durvalumab 84Drug Therapy 84osimertinib 81atezolizumab 58Vinorelbine 53Gefitinib 53Radiosurgery 49Cetuximab 39Taxes 37130-nm albumin-bound paclitaxel 35Ipilimumab 34anlotinib 33Surgical Procedures, Operative 33Magnetic Resonance Spectroscopy 33Etoposide 30Albumin-Bound Paclitaxel 29tislelizumab 27icotinib 27Specimen Handling 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Carcinoma, Non-Small-Cell Lung × Valacyclovir × Clear all
NCT03004183 2024-10-15

STOMP

The Methodist Hospital Research Institute

Phase 2 Completed
57 enrolled 12 charts
BreastThoracic

Carcinoma, Non-Small-Cell Lung, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡